Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.
نویسندگان
چکیده
In clinical practice, physicians are confronted with the question of whether patients with terminal renal failure can be safely offered targeted drugs such as sunitinib. However, clinical trials leading to the approval have excluded these patients. We present the case of one patient requiring chronic hemodialysis and treated with escalating doses of sunitinib according to a pharmacological monitoring. The focus was on the clinical safety, pharmacokinetics assessment and the oncological outcome.
منابع مشابه
Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib
Sunitinib has been approved for the treatment of advanced and/or metastatic renal cell carcinoma (RCC). Information on the dosage adjustment of sunitinib for patients undergoing hemodialysis is limited. Especially, efficacy and tolerance of sunitinib at a low dose in such patients are not fully understood. Thus, we examined the effect of hemodialysis on the pharmacokinetics, safety and efficacy...
متن کاملSevere toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report
BACKGROUND Sunitinib is a multi-targeted tyrosine kinase inhibitor that is approved for treatment of renal cell carcinoma as an oral anticancer drug. Therapeutic drug monitoring of total sunitinib (sunitinib and N-desethyl sunitinib) is used in our hospital to improve therapeutic efficacy, while preventing adverse effects. Here, we report the first case of a patient with metastatic renal cell c...
متن کاملIntolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatment of metastatic renal cell carcinoma (RCC). However, neither an appropriate dose nor dosing schedule of sunitinib has yet been established for patients with metastatic RCC who are on hemodialysis. Here, we report on two hemodialysis patients who received sunitinib to treat metastatic RCC. Sunitinib was p...
متن کاملSunitinib Induced Immune Thrombocytopenia
Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ systems including hematologic system. Although the neutropenia and thrombocytopenia commonly happens as Gra...
متن کاملSunitinib Induced Immune Thrombocytopenia
Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ systems including hematologic system. Although the neutropenia and thrombocytopenia commonly happens as Gra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 22 9 شماره
صفحات -
تاریخ انتشار 2011